Sort   by:  
 Page size 
MetabolomicsFbxo7 promotes Cdk6 activity to inhibit PFKP and glycolysis in T cells
Not available
ORGANISM(S): Mus musculus 
ST001986 | MetabolomicsWorkbench
MetabolomicsRBC Balanced Immuno-inflammatory Signatures Identify Advanced Breast Cancer Patients on CDK4/6 Inhibitors at Increased Risk of Progression and Death

Recent studies show red blood cell (RBC) plays an essential role in regulating immunity. Nevertheless, the association of immuno-inflammatory parameters, especially RBC balanced signatures, with survival outcomes and adverse events still require investigation for advanced breast cancer (ABC) pati...

2025-04-15 | MTBLS10792 | MetaboLights
MetabolomicsCDK4/6 inhibitor-mediated cell overgrowth triggers an osmotic stress response and chronic p38MAPK activation to promote long-term cell cycle arrest

Cell size and the cell cycle are intrinsically coupled and abnormal increases in cell size are associated with senescence and permanent cell cycle arrest. The mechanism by which overgrowth primes cells to withdraw from the cell cycle remains unknown. We investigate this here using CDK4/6 inhibito...

2025-10-24 | MTBLS5868 | MetaboLights
TranscriptomicsCDK6 as key regulator of hematopoietic and leukemic stem cell activation.
The cyclin-dependent kinases (CDK) CDK6 and CDK4 have redundant functions in regulating cell-cycle progression. We describe a novel role for CDK6 in hematopoietic and leukemic stem cells (HSCs and LSCs) that exceeds its function as cell-cycle regulator. Although hematopoiesis appears regular under s...
ORGANISM(S): Mus musculus 
2015-02-20 | E-GEOD-62012 | biostudies-arrayexpress
ProteomicsCDK6 degradation is counteracted by p16INK4A and p18INK4C in AML
Cyclin-dependent kinase 6 (CDK6) represents a novel therapeutic target for the treatment of certain subtypes of acute myeloid leukemia (AML). CDK4/6 kinase inhibitors have been widely studied in many cancer types and their effects may be limited by primary and secondary resistance mechanisms. CDK4/6...
ORGANISM(S): Mus musculus (Mouse) 
2022-04-04 | PXD032216 | Pride
Cdk6 P16 Degrader P18 Cdkn2c Ink4 Cdkn2a Aml 
ProteomicsPhosphochromatome profiling of C-terminally truncated CDK6
Pre/pro-B-cell lines were generated from bone marrow cells of Cdk6-/- mice by retroviral overexpression of the BCR-ABL (p185) fusion oncogene. These cell lines were transduced with constructs expressing HA-tagged versions of wildtype Cdk6 or of a C-terminally truncated variant of Cdk6 (HA-Cdk6-ΔC)....
ORGANISM(S): Mus musculus (Mouse) 
2024-12-19 | PXD059037 | Pride
Cycline dependent kinase 6 C-lobe 
ProteomicsInteractome of C-terminally truncated CDK6
Pre/pro-B-cell lines were generated from bone marrow cells of Cdk6-/- mice by retroviral overexpression of the BCR-ABL (p185) fusion oncogene. These cell lines were transduced with constructs expressing HA-tagged versions of wildtype Cdk6 or of a C-terminally truncated variant of Cdk6 (HA-Cdk6-ΔC)....
ORGANISM(S): Mus musculus (Mouse) 
2024-12-19 | PXD058474 | Pride
Cyclin-dependent kinase 6 C-terminus Ip mass spec 
ProteomicsBroad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma
Lenvatinib is the FDA-approved targeted drug for advanced hepatocellular carcinoma (HCC), but the efficacy is modest due to drug resistance. Tumor kinome re-wiring governs drug resistance in resistant cancer cells, which is an obstacle for efficient cancer therapy. Therefore, identification the kina...
ORGANISM(S): Homo sapiens (Human) 
2023-09-29 | PXD038152 | Pride
Beta-catenin Cancer stemness Hcc Cdk6 Lenvatinib 
TranscriptomicsExpression profile of BCR-ABL1-transformed, Cdk4 R24C, Cdk6 R31C cell lines
Cdk4 and Cdk6 are two related kinases that bind D-type cyclins and regulate cell cycle progression. Due to their relevance in cancer, Cdk4/6 inhibitors are currently in advanced clinical trials in multiple tumor types. Cdk4/6 are inhibited by INK4 proteins that exert tumor suppressing functions. To ...
ORGANISM(S): Mus musculus 
2014-11-04 | E-GEOD-59024 | biostudies-arrayexpress
ProteomicsProteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multiple myeloma. However, virtually all patients eventually relapse due to acquired drug resistance with resistance-causing genetic alterations being found only in a small subset of cases. Here, we ...
ORGANISM(S): Homo sapiens (Human) 
2021-12-17 | PXD021265 | Pride
Multiple myeloma Tmt Lc-ms Cdk6 
Sort   by:  
 Page size